1. Introduction {#sec1}
===============

Renal cell cancer (RCC) represents the deadliest neoplasm of the urinary tract, due to the fact that a majority of patients are diagnosed at a very advanced stage \[[@B1], [@B2]\]. Tumor progression is based on various molecular mechanisms, and thus, further examinations of RCC tumor biology are necessary in order to understand the progression and, furthermore, to identify novel biomarkers for diagnosis and prognosis of RCC \[[@B1], [@B3]--[@B5]\].

Among other mechanisms, cytokines and chemokines are suspected to play a crucial role in proliferation and progression of various malignancies. For instance, CCL11 controls cancer cell growth and invasion in ovarian cancer and CCL21 as well as CCR7 represent pivotal regulators of bladder cancer progression \[[@B6], [@B7]\]. Moreover, IL17, as a representative of interleukins, is associated with lung and colorectal cancer progression and predicts poor prognosis in breast cancer \[[@B8]--[@B10]\]. Even though some studies suggested an impact in RCC, the role of cytokines and chemokines in RCC progression is poorly understood \[[@B1], [@B11], [@B12]\]. From a clinical point of view, cytokine and chemokine secretion into the blood stream makes them very suitable as noninvasive clinical markers.

In the study presented here, we used an RCC model system consisting of four malignant RCC cell lines compared to a nonmalignant renal cell line. After classification of the RCC cells in cell lines of high and low cell growth rates, a transcriptional profiling specific for 84 cytokines and chemokines ([Table 1](#tab1){ref-type="table"}) was carried out and compared to the corresponding cell growth properties. The aim of this analysis was to identify cell growth-associated cytokines and chemokines by comparison of malignant and nonmalignant expression patterns, particularly with regard to the identification of putative biomarkers for RCC progression.

2. Materials and Methods {#sec2}
========================

2.1. Cell Culture {#sec2.1}
-----------------

RCC cell lines Caki-1, 786-O, A498 (Cell Lines Service, Eppelheim, Germany), and RCC4 (Sigma-Aldrich, München, Germany) and the nonmalignant renal cell line RC-124 (Cell Lines Service) were used. Caki-1 and A498 cells were cultivated in a minimum essential medium (MEM) supplemented with 79.6 mg/l nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% penicillin/streptomycin (P/S), and 10% FBS (PAN Biotech, Aidenbach, Germany). 786-O cells were propagated in RPMI 1640 medium containing 2 mM L-glutamine, 1% P/S, and 10% FBS (PAN Biotech); RCC4 cells were cultivated in Dulbecco\'s Modified Eagle Medium (DMEM) with 1 mM sodium pyruvate, 1% P/S, and 10% FBS (PAN Biotech); and RC-124 cells were cultivated in McCoy\'s 5a medium supplemented with 2 mM L-glutamine, 1% P/S, and 10% FBS (PAN Biotech). All cells were propagated in a humidified atmosphere (37°C, 5% CO~2~).

2.2. Proliferation Assay {#sec2.2}
------------------------

Proliferation of cells was examined by cell counting (CASY Cell Analyzer, Roche Applied Science, Mannheim, Germany). Adherent cells, detached by trypsin/ethylenediaminetetraacetic acid (EDTA) treatment, were suspended in CASYton (Roche Applied Science) as 1 : 100 dilution. Measurement was performed using a capillary of 150 *μ*m in diameter and cell line-specific gate settings to discriminate between living cells, dead cells, and cellular debris (Caki-1: 8.57 *μ*m/15.4 *μ*m, 786-O: 6.9 *μ*m/14.7 *μ*m, RCC4: 8.5 *μ*m/15.75 *μ*m, A-498: 7.2 *μ*m/15.75 *μ*m, and RC-124: 6.5 *μ*m/12.75 *μ*m).

2.3. Quantitative DNA Array {#sec2.3}
---------------------------

RCC cells and nonmalignant RC-124 cells were grown on a 6-well cell culture plate to 80% confluency and total RNA was prepared (peqGOLD TriFast reagent, Peqlab Biotechnology, Erlangen, Germany). Analysis of 84 human cytokines and chemokines ([Table 1](#tab1){ref-type="table"}) was performed using the Human Cytokines & Chemokines RT^2^ Profiler PCR Array (Qiagen, Hilden, Germany) according to the supplier\'s instructions (<http://www.sabiosciences.com>). Briefly, 0.5 *μ*g of total RNA was reversely transcribed and polymerase chain reaction (PCR) was done on a CFX96 Real-Time System (Bio-Rad, Munich, Germany) and analyzed with the CFX Manager software (Bio-Rad).

2.4. Enzyme-Linked Immunosorbent Assay (ELISA) {#sec2.4}
----------------------------------------------

IL6, IL8, IL11, IL15, and VEGF concentrations in cell culture supernatant of RCC cells and nonmalignant RC-124 cells were determined by use of target-specific DuoSet ELISA kits with a Substrate Reagent Pack containing stabilized hydrogen peroxide and tetramethylbenzidine (all R&D, Minneapolis, MN, USA) according to the supplier\'s instructions. Cells were sedimented (1.3 × g, 5 min), the supernatant was incubated with capture antibodies (overnight, 4°C), and soluble antigens were determined applying the BMG FLUOstar OPTIMA Microplate Reader with OPTIMA software 2.10 (BMG Labtech, Offenbach, Germany). Each sample was analyzed in duplicates.

2.5. Statistics {#sec2.5}
---------------

For data evaluation, the graphics and statistics software Graph Pad Prism V5.01 (GraphPad Software, La Jolla, CA, USA) was used. Principal component analysis (PCA) was performed using Multibase 2015 software (NumericalDynamics.Com, Tokyo, Japan).

3. Results {#sec3}
==========

In contrast to the elevated proliferation rates of Caki-1 and 786-O cells compared to those of nonmalignant RC-124 cells, both, RCC4 and A498 cells, showed a markedly reduced cell growth ([Figure 1](#fig1){ref-type="fig"}). These differences in proliferation prompted us to investigate whether cytokines and chemokines may control the individual growth properties of the RCC cell lines.

Performing the RT^2^ Profiler PCR Array Human Cytokines & Chemokines, the expression of 84 target mRNAs ([Table 1](#tab1){ref-type="table"}) was measured. From these 84 factors, which have been examined at the intracellular mRNA level, the 5 cytokines IL6, IL8, IL11, IL15, and VEGF have been exemplarily chosen for verification at the extracellular protein level via ELISA. mRNA concentrations of IL6, IL8, IL11, IL15, and VEGF appeared to correspond to the levels of secreted proteins of the RCC cells and the nonmalignant renal cell line ([Figure 2](#fig2){ref-type="fig"}). The transcript pattern of IL6, IL8, and IL15 was very comparable to the levels of secreted proteins in all cell lines. However, there were differences in Caki-1 cells with respect to the low level of secreted IL11 protein and the high level of secreted VEGF protein compared to that of intracellular mRNA. Exactly opposite results were found with respect to 786-O cells. Nevertheless, comparison of cytokines\' mRNA and protein levels revealed a clear correlation indicating mRNA arrays\' applicability for expression analyses of cytokines and chemokines.

Furthermore, a global normalized PCA was performed and used as quality check. PCA was carried out on the concentrations of all of the detected cytokines and chemokines in all of the five cell lines ([Figure 3](#fig3){ref-type="fig"}) dividing cancer and noncancer cells (PC1) and defining individual characteristics of all cell lines (PC2). As expected, the five cell lines used in this study were divided correctly into two major groups corresponding to malignant *versus* nonmalignant physiology.

Performing the Human Cytokines & Chemokines RT^2^ Profiler PCR Array, the expression of various cytokines and chemokines for each of the cell lines was analyzed compared to the nonmalignant cell line RC-124. The following 32 cytokines and chemokines were not expressed: ADIPQ, BMP7, CCL1, CCL17, CCL18, CCL19, CCL22, CCL24, CCL3, CCL8, CD40LG, CXCL13, CXCL9, FASLG, IFNG, IL10, IL12B, IL13, IL16, IL17A, IL17F, IL21, IL22, IL24, IL3, IL4, IL5, IL9, LTA, THPO, TNFSF11, and XCL1.

52 factors were modulated compared to RC-124 cells ([Figure 4](#fig4){ref-type="fig"}). The group of chemokines ([Figure 4(a)](#fig4){ref-type="fig"}) was dominated by the overexpression of CCL20, CXCL10, and foremost CCL5 with more than a 100-fold overexpression. Most striking was the strong upregulation of these three chemokines in A498 cells, even compared to the other RCC cell lines. Within the family of growth factors, a more balanced distribution pattern of the factors was demonstrated ([Figure 4(b)](#fig4){ref-type="fig"}). However, only CNTF, CSF1, CSF3, LIF, MSTN, and VEGFA were detectable in all of the four malignant cell lines.

Five members of the TNF superfamily were detected ([Figure 4(c)](#fig4){ref-type="fig"}); however, only TNFSF13B was strongly overexpressed in all of the four malignant cell lines, dominated by an upto 25-fold overexpression in Caki-1 and RCC4 cells. Considering the family of interleukins ([Figure 4(d)](#fig4){ref-type="fig"}), a total of 13 different factors were detected with an upregulated expression of the interleukins IL1A, IL1B, and IL1RN in each of the 4 malignant cell lines.

4. Discussion {#sec4}
=============

The process of tumorigenesis is driven by several mechanisms including an increased proliferation, angiogenesis, and immunomodulation \[[@B13]\]. Cytokines and chemokines, in general, are primarily regulators of immune defense. CCL5, in particular, supports leukocyte diapedesis by integrin induction \[[@B14], [@B15]\]. Interestingly, CCL5 expression in all four RCC cell lines was highly upregulated. Since tumorigenesis is associated with inflammatory response, elevated CCL5 secretion by RCC cells may be part of cancer-related inflammation. Corresponding to this observation is the finding that the expression levels of proinflammatory interleukins IL1A and IL1B are increased in all of the four RCC cell lines. Interestingly, overexpression of the anti-inflammatory IL1RN \[[@B16]\] could only be observed in the lowly proliferative RCC4 and A498 cells. This could mean that IL1RN may interfere with antiproliferative pathways or that anti-inflammatory processes generally attenuate cell growth.

Within the TNF superfamily, TNFSF13B is significantly overexpressed in all four RCC cell lines. Looking at the large differences in cellular growth of highly proliferative Caki-1 and 786-O and lowly proliferative RCC4 and A498 cell lines, however, classification of TNFSF13B as a proliferative factor in RCC, as has been done in previous studies \[[@B17]\], could not be clearly confirmed.

As expected, expression levels of proliferative cytokines, for example, CSF-1, CSF-3, NODAL, and VEGFA, correlated with the cell growth rates of the highly proliferative (Caki-1, 786-O) and the lowly proliferative (RCC4, A498) RCC cells. This observation has been confirmed by several studies. CSF-1 and VEGFA expression is associated with RCC progression and bad prognosis for patient survival \[[@B11], [@B18], [@B19]\]. Furthermore, elevated levels of NODAL, a member of the TGF*β* superfamily, confer enhanced tumorigenicity \[[@B20]--[@B23]\]. Expectedly, strongly overexpressed proliferative factors, for example, VEGFA and NODAL, may represent novel prognostic markers for RCC.

Vice versa, the expression of BMP6 was significantly increased in the lowly proliferative cell lines RCC4 and A498, whereas an expression in highly proliferative Caki-1 and 786-O cells was not detectable. Since BMP6 is considered to be a tumor suppressor in breast cancer \[[@B24]\], upregulation of BMP6 in RCC cells may contribute to attenuated cell growth of RCC4 and A498 cells compared to that of the nonmalignant cell line RC-124.

Taken together, there are a number of cytokines and chemokines which are differentially expressed not only in malignant and nonmalignant renal cells but also in the four RCC cell lines. These results may reflect heterogeneity among RCC patients as well as among RCC subtypes. In addition, this may suggest a functional substitution of members of the cytokine/chemokine system due to an activation of alternative factors involved in cytokine/chemokine signalling. Notably, two proliferative factors (VEGFA, NODAL) and a tumor suppressive factor (BMP6) have been found which may significantly contribute to the malignant phenotype of RCC and thus may be suitable as novel marker proteins in RCC diagnosis and therapy.
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![Cellular growth of the RCC cell lines Caki-1, 786-O, RCC4, and A498 as well as the nonmalignant renal cell line RC-124. Cellular growth was examined at indicated time points utilizing a CASY Cell Counter and Analyzer Model TT (Roche Applied Science). Results are expressed as the mean ± SD of cell count.](ACP2017-7190546.001){#fig1}

![Comparison of mRNA levels and protein levels of selected cytokines. Steady-state levels of intracellular mRNA levels and extracellular protein levels of IL6 (a), IL8 (b), IL11 (c), IL15 (d), and VEGF (e) were assessed by quantitative DNA array (Human Cytokines & Chemokines RT^2^ Profiler PCR Array; Qiagen) and enzyme-linked immunosorbent assay (ELISA) analysis, respectively. mRNA amounts are expressed as relative mRNA levels normalized to nonmalignant RC-124 cells (RC-124 mRNA = 1.0). Protein levels are expressed as pg protein/ml cell culture supernatant.](ACP2017-7190546.002){#fig2}

![Principal component analysis (PCA) of the cytokine and chemokine expression. The RCC cell lines Caki-1, 786-O, RCC4, and A498 as well as the nonmalignant renal cell line RC-124 were plotted in a two-dimensional coordinate plane defined by the principal components 1 (PC1) and 2 (PC2) analyzing the expression data of all cytokines and chemokines measured by the DNA array (Human Cytokines & Chemokines RT^2^ Profiler PCR Array; Qiagen). Clustering of the malignant cells is indicated by a grey triangle.](ACP2017-7190546.003){#fig3}

![Expression profile of cytokines and chemokines in RCC cell lines. Expression data of cytokines and chemokines in the RCC cell lines Caki-1, 786-O, RCC4, and A498 as well as in the nonmalignant renal cell line RC-124 were measured performing a DNA array (Human Cytokines & Chemokines RT^2^ Profiler PCR Array; Qiagen) and expressed as relative mRNA normalized to nonmalignant RC-124 cells (RC-124 = 1.0). Cytokines and chemokines were classified into the four groups of chemokines (a), growth factors (b), TNF superfamily members (c), and interleukins (d).](ACP2017-7190546.004){#fig4}

###### 

Human Cytokines & Chemokines RT^2^ Profiler PCR Array (Qiagen). Abbreviation (symbol) and full name/function (description) of the 84 cytokines and chemokines analyzed by the PCR array. The column "detectable" indicates whether the factor was detected (+) or not detected (−) within this study.

  Number            Symbol      Description                                                       Detectable
  ----------------- ----------- ----------------------------------------------------------------- ------------
  Chemokines                                                                                      
   1                C5          Complement component 5                                            \+
   2                CCL1        Chemokine (C-C motif) ligand 1                                    −
   3                CCL2        Chemokine (C-C motif) ligand 2                                    \+
   4                CCL3        Chemokine (C-C motif) ligand 3                                    −
   5                CCL5        Chemokine (C-C motif) ligand 5                                    \+
   6                CCL7        Chemokine (C-C motif) ligand 7                                    \+
   7                CCL8        Chemokine (C-C motif) ligand 8                                    −
   8                CCL11       Chemokine (C-C motif) ligand 11                                   \+
   9                CCL13       Chemokine (C-C motif) ligand 13                                   \+
   10               CCL17       Chemokine (C-C motif) ligand 17                                   −
   11               CCL18       Chemokine (C-C motif) ligand 18                                   −
   12               CCL19       Chemokine (C-C motif) ligand 19                                   −
   13               CCL20       Chemokine (C-C motif) ligand 20                                   \+
   14               CCL21       Chemokine (C-C motif) ligand 21                                   \+
   15               CCL22       Chemokine (C-C motif) ligand 22                                   −
   16               CCL24       Chemokine (C-C motif) ligand 24                                   −
   17               CXCL1       Chemokine (C-X-C motif) ligand 1                                  \+
   18               CXCL2       Chemokine (C-X-C motif) ligand 2                                  \+
   19               CXCL5       Chemokine (C-X-C motif) ligand 5                                  \+
   20               CXCL9       Chemokine (C-X-C motif) ligand 9                                  −
   21               CXCL10      Chemokine (C-X-C motif) ligand 10                                 \+
   22               CXCL11      Chemokine (C-X-C motif) ligand 11                                 \+
   23               CXCL12      Chemokine (C-X-C motif) ligand 12                                 \+
   24               CXCL13      Chemokine (C-X-C motif) ligand 13                                 −
   25               CXCL16      Chemokine (C-X-C motif) ligand 16                                 \+
   26               CX3CL1      Chemokine (C-X3-C motif) ligand 1                                 \+
   27               GPI/AMF     Glucose-6-phosphate isomerase                                     \+
   28               IFNA2       Interferon, alpha 2                                               \+
   29               MIF         Macrophage migration inhibitory factor                            \+
   30               PPBP        Proplatelet basic protein (chemokine (C-X-C motif) ligand 7)      \+
   31               SPP1        Secreted phosphoprotein 1                                         \+
   32               XCL1        Chemokine (C motif) ligand 1                                      −
  Growth factors                                                                                  
   33               BMP2        Bone morphogenetic protein 2                                      \+
   34               BMP4        Bone morphogenetic protein 4                                      \+
   35               BMP6        Bone morphogenetic protein 6                                      \+
   36               BMP7        Bone morphogenetic protein 7                                      −
   37               CNTF        Ciliary neurotrophic factor                                       \+
   38               CSF1        Colony stimulating factor 1 (macrophage)                          \+
   39               CSF2        Colony stimulating factor 2 (granulocyte-macrophage)              \+
   40               CSF3        Colony stimulating factor 3 (macrophage)                          \+
   41               LIF         Leukemia inhibitory factor (cholinergic differentiation factor)   \+
   42               MSTN        Myostatin                                                         \+
   43               NODAL       Nodal homolog (mouse)                                             \+
   44               OSM         Oncostatin M                                                      \+
   45               TGFB2       Transforming growth factor, beta 2                                \+
   46               THPO        Thrombopoietin                                                    −
   47               VEGFA       Vascular endothelial growth factor A                              \+
  TNF superfamily                                                                                 
   48               CD40LG      CD40 ligand                                                       −
   49               FASLG       Fas ligand (TNF superfamily, member 6)                            −
   50               LTA         Lymphotoxin alpha (TNF superfamily, member 1)                     −
   51               LTB         Lymphotoxin beta (TNF superfamily, member 3)                      \+
   52               TNF         Tumor necrosis factor                                             \+
   53               TNFRSF11B   Tumor necrosis factor receptor superfamily, member 11b            \+
   54               TNFSF10     Tumor necrosis factor (ligand) superfamily, member 10             \+
   55               TNFSF11     Tumor necrosis factor (ligand) superfamily, member 11             −
   56               TNFSF13B    Tumor necrosis factor (ligand) superfamily, member 13b            \+
  Interleukins                                                                                    
   57               IL1A        Interleukin 1, alpha                                              \+
   58               IL1B        Interleukin 1, beta                                               \+
   59               IL1RN       Interleukin 1 receptor antagonist                                 \+
   60               IL2         Interleukin 2                                                     \+
   61               IL3         Interleukin 3 (colony-stimulating factor, multiple)               −
   62               IL4         Interleukin 4                                                     −
   63               IL5         Interleukin 5 (colony-stimulating factor, eosinophil)             −
   64               IL6         Interleukin 6 (interferon, beta 2)                                \+
   65               IL7         Interleukin 7                                                     \+
   66               IL8         Interleukin 8                                                     \+
   67               IL9         Interleukin 9                                                     −
   68               IL10        Interleukin 10                                                    −
   69               IL11        Interleukin 11                                                    \+
   70               IL12A       Interleukin 12A                                                   \+
   71               IL12B       Interleukin 12B                                                   −
   72               IL13        Interleukin 13                                                    −
   73               IL15        Interleukin 15                                                    \+
   74               IL16        Interleukin 16                                                    −
   75               IL17A       Interleukin 17A                                                   −
   76               IL17F       Interleukin 17F                                                   −
   77               IL18        Interleukin 18 (interferon-gamma-inducing factor)                 \+
   78               IL21        Interleukin 21                                                    −
   79               IL23A       Interleukin 23, alpha subunit p19                                 \+
   80               IL22        Interleukin 22                                                    −
   81               IL24        Interleukin 24                                                    −
   82               IL27        Interleukin 27                                                    \+
  Cytokines                                                                                       
   83               ADIPOQ      Adiponectin, C1Q and collagen domain containing                   −
   84               IFNG        Interferon, gamma                                                 −
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